Antimicrobial Agents and Chemotherapy · 2013 · 52 citations · 14 references
MedicinePharmacokineticsPharmacologyAntimicrobial PharmacologyAntimicrobial PharmacotherapyInfectious Disease PharmacotherapyAntibacterial AgentsAntibacterial PharmacologyAntibacterial TherapyPharmacokinetics Of AntimicrobialsTuberculosis PharmacotherapyIntraperitoneal AdministrationMicrobial Iron AcquisitionMycobacterium Tuberculosis InfectionMycobacterium Tuberculosis PathogenesisNovel Antibacterial AgentsNovel Antibacterial Drug DiscoveryPharmacokinetic Parameter AnalysisPharmacokinetic Study Design
Mycobactin biosynthesis in Mycobacterium tuberculosis facilitates iron acquisition, which is required for growth and virulence. The mycobactin biosynthesis inhibitor salicyl-AMS [5'-O-(N-salicylsulfamoyl)adenosine] inhibits M. tuberculosis growth in vitro under iron-limited conditions. Here, we conducted a single-dose pharmacokinetic study and a monotherapy study of salicyl-AMS with mice. Intraperitoneal injection yielded much better pharmacokinetic parameter values than oral administration did. Monotherapy of salicyl-AMS at 5.6 or 16.7 mg/kg significantly inhibited M. tuberculosis growth in the mouse lung, providing the first in vivo proof of concept for this novel antibacterial strategy.
14
L A Collins, Scott G. Franzblau · Antimicrobial Agents and Chemotherapy · 1997 · 1.6K citations · Full text
Veterinary Medicine, Infectious Diseases, Antimicrobial Pharmacology +7
James J. De Voss, K. Rutter, Benjamin G. Schroeder et al. · Proceedings of the National Academy of Sciences · 2000 · 527 citations · Full text
Luis E. N. Quadri, Jason K. Sello, Thomas A. Keating et al. · Chemistry & Biology · 1998 · 420 citations · Full text
Juliano Timm, Frank A. Post, Linda‐Gail Bekker et al. · Proceedings of the National Academy of Sciences · 2003 · 280 citations · Full text